scilogo.jpg
SciSparc Successfully Completed The Development of its Proprietary Drug Candidate SCI-110 for its Upcoming Phase IIb Study In Tourette Syndrome
June 29, 2022 08:30 ET | SciSparc Ltd
TEL AVIV, Israel, June 29, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty, clinical-stage pharmaceutical company focusing on the development of...
Hopebridge shares tips for a sensory-friendly Fourth of July
June 27, 2022 07:00 ET | Hopebridge
Indianapolis, IN, June 27, 2022 (GLOBE NEWSWIRE) -- Family, friends and community members can make Independence Day more enjoyable [KA1] for their loved ones with autism spectrum disorder (ASD) this...
scilogo.jpg
SciSparc Announces Ethics Committee Approval to Conduct its Clinical Trial in Autism Spectrum Disorder
June 23, 2022 09:30 ET | SciSparc Ltd
The Soroka University Ethics Committee Approval Received to Conduct a Clinical trial with SciSparc’s Proprietary SCI-210 Treatment TEL AVIV, Israel, June 23, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd....
CentralReach Launches avail® 2.0, an Innovative Assistive Technology to Support the Autism and IDD Workforce – Providing a Renewed Hope for More Neurodiversity in the Workplace
June 21, 2022 10:59 ET | CentralReach
Fort Lauderdale, FL, June 21, 2022 (GLOBE NEWSWIRE) -- CentralReach, the leading provider of Autism and IDD Care Software, today announced the launch of the newest version of avail®, which provides...
Hopebridge founder recognized for community achievements in health care
June 15, 2022 07:00 ET | Hopebridge
Indianapolis, IN, June 15, 2022 (GLOBE NEWSWIRE) -- Kim Strunk, the founder of Hopebridge Autism Therapy Centers, one of the largest autism therapy providers in the nation, has been honored by the...
CentralReach Launches Registration for its 4th Annual In-Person CR Unite Conference – the Premier Event for Tech-Enabled Autism and IDD Care
June 14, 2022 11:13 ET | CentralReach
Fort Lauderdale, FL, June 14, 2022 (GLOBE NEWSWIRE) -- CentralReach, the leading provider of Autism and IDD Care software, today launched registration for its fourth annual CR Unite conference, now...
CentralReach Expands Its PreK-12 Education Software Offering Through the Acquisition of LiftEd, a Purpose-Built Software Application for Special Education Programs
June 09, 2022 16:57 ET | CentralReach
Fort Lauderdale, FL, June 09, 2022 (GLOBE NEWSWIRE) -- CentralReach, the leading provider of Autism and IDD Care Software, today announced the acquisition of LiftEd, a cloud-based software that...
Logo Blue Main.png
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
June 01, 2022 06:00 ET | Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
Logo Blue Main.png
Neuronascent Receives FDA Rare Pediatric Drug Designation for NNI-351 Treatment for Fragile X Syndrome
May 24, 2022 06:00 ET | Neuronascent, Inc.
ROCKVILLE, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc., a clinical-stage biopharmaceutical company discovering and developing neuron-generating therapies for rare developmental...
CentralReach Defines New Software Category to Address Growing Autism and IDD Care Gap™ and Reveals New Brand to Better Align to its Expanded Mission
May 11, 2022 11:15 ET | CentralReach
Fort Lauderdale, May 11, 2022 (GLOBE NEWSWIRE) -- CentralReach today announced the creation of a new category, Autism and IDD Care Software, to address the need for solutions to support the lifelong...